Abstract
The study included 49 patients with chronic obstructive pulmonary disease stage III combined CHD. All patients were divided into two comparable groups: first - 26 people to pathogenetic therapy of COPD received atorvastatin, the second - 23 people did not receive treatment with atorvastatin. Follow-up was 3 months. In both groups lipid metabolism, systemic inflammation, spirometry were analyzed. Among patients treated with atorvastatin a significant reduction in markers of inflammation, normalization of blood lipid profile, as well as slowing the progression of respiratory failure were revealed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
